Posted by ABMN Staff on Apr 23rd, 2024
Roth Mkm reaffirmed their buy rating on shares of Iradimed (NASDAQ:IRMD – Free Report) in a report released on Monday, Benzinga reports. The brokerage currently has a $65.00 price target on the medical equipment provider’s...
More of this article »